Our data has shed new light on the emerging concept that repositioning calcium signalling-blocking drugs, such as CCBs, as an entirely novel class of IGF-1R-targeting chemopreventive agents without the potential deleterious toxicities of metabolic disorders. Here, IGF1R is linked to metabolic disease.